Doxycycline Combined with NB-UVB Phototherapy for Acquired Reactive Perforating Collagenosis
Authors Gao L, Gu L, Chen Z, Cao S
Received 10 July 2020
Accepted for publication 21 August 2020
Published 24 September 2020 Volume 2020:16 Pages 917—921
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Limu Gao, Lixiong Gu, Zhen Chen, Shuanglin Cao
Department of Dermatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, People’s Republic of China
Correspondence: Shuanglin Cao
Department of Dermatology, Affiliated Hospital of Nantong University, 20th Xisi Road, Nantong, People’s Republic of China
Email [email protected]
Background: Acquired reactive perforating collagenosis is a rare skin disease characterized by the discharge of collagen fibers through the epidermis. There is no standard treatment for this disease currently. Here, we report a case of ARPC that has been successfully treated and cured.
Case Description: A 32-year-old man developed severe itching papules on his torso and limbs for 3 months. Skin lesions were keratotic papules scattered on the limbs and trunk, with a diameter of 3 to 12 mm. Some lesions had umbilical recesses and the shape of a crater with positive isomorphic reactions. The patient scratched his severe itching lesions which merged into large ones. This patient had histories of hypertension and dilated cardiomyopathy with mild congestive heart failure. The clinical presentation and histopathology of skin lesions met Faver’s diagnostic criteria for ARPC.
Treatment: Oral Doxycycline 100mg/d, NB-UVB phototherapy 3 times a week with initial dose 400mJ/cm2, gradually increased to 1200mJ/cm2(total cumulative dose 16700J/cm2).
Outcomes: After a week of treatment, the patient’s itching symptoms were significantly reduced and stopped presenting any new skin lesions. Most of the lesions healed in 6 weeks of treatment.
Lessons: Doxycycline combined with NB-UVB may be an effective treatment for ARPC.
Keywords: acquired reactive perforating collagenosis, doxycycline, NB-UVB, hypertension
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]